Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.
Special protocols are required to ensure the safety of patients undergoing bone marrow transplants.
In the April 2024 issue of Oncology Nursing News, stories focus on bladder-preserving treatment options in bladder cancer, recent FDA approvals, conference news, and embracing vicarious resilience.
Oncology practices can create more access to care by leveraging the use of APPs, empowering nurses to practice at the top of their licensure, utilizing nurse navigators, and planning ahead.
92% of those over 70 say they are comfortable with telehealth.
Patients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.
Heather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.
Advanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.
The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.
A global study revealed that patients and caregivers alike reported insufficient knowledge surrounding renal cell carcinoma.
The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.
A Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
Heather Simonsen, MA, outlines some ways for health care professionals to feel more comfortable in the spotlight.
Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Compared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.
Dawn Landolph, RN, BSN, OCN, MPA, provides an in-depth look at adagrasib for the treatment of patients with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer in a downloadable reference sheet.
Oncology nurses can help their patients navigate misinformation that they may find online.
Oncology nurses are often the main point of contact for newly diagnosed patients with cancer. We have the opportunity to ensure that each person starts their journey with equality and equity on their side.
Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.
Patients with depression had a 37% higher risk of dying from their disease than patients without a mental health diagnosis.
Agnes Pilecki, BSN, RN, a nurse on Barbara Ann Karmanos Cancer Institute’s bone marrow transplant unit, has been named the Metro Detroit Oncology Nursing Society’s (MDONS) Outstanding Oncology Nurse of the Year.
April is National Minority Health Month, highlighting the need for health care and community sectors to come together and improve cancer outcomes for underserved populations.
Reanne Booker, MN, NP, highlights factors that make a patient a good candidate for palliative radiation.
Although technology alone can’t solve clinician burnout, it can provide the means for organizations to provide better care while increasing efficiency and alleviating stress.
Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.
Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.
Cheryl VerStrate, DNP, AGPCNP-BC, OCN, discusses why nurses should be prepared to discuss direct-to-consumer genomic testing with their patients.
Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.